The effects of the Korean reference value on the prevalence of osteoporosis and the prediction of fracture risk

BMC Musculoskeletal Disorders

Hyunhee Choi⁵  Myungjin Choi⁵  Kyutae Park⁵  Eun-Gyung Hong¹  Doo-Man Kim³  Sung-Hee Ihm²  Hyung Joon Yoo⁴  Ohk-Hyun Ryu⁵  Jaemyung Yu⁴  Moon-Gi Choi⁵  Sungwha Lee⁵ 

[1] Department of Internal Medicine, Dongtan Sacred Heart Hospital, Hallym Medical University, 7, Keunjaebong-gil, Hwaseong-si 445-907, Gyeonggi-do, South Korea;Department of Internal Medicine, Hallym University Sacred Heart Hospital, 22, Gwanpyeong-ro 170 beon-gil, Dongan-gu, Anyang-si 431-796, Gyeonggi-do, South Korea;Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym Medical University, 150, Seongan-ro, Seoul 134-701, Gangdong-gu, South Korea;Department of Internal Medicine, Gangnam Sacred Heart Hospital, Hallym Medical University, 1, Singil-ro, Seoul 150-950, Yeongdeungpo-gu, South Korea;Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym Medical University, Chuncheon Sacred Heart Hospital, 77, Sakju-ro, Chuncheon-si, Gangwon-do, South Korea

关键词: T-score;    Reference;    Prevalence;    Prediction of fracture risk;    Osteoporosis;    Osteopenia;    Korean reference value;    FRAX;    Fracture risk;    Bone mineral density;   

Others  :  1161060
DOI  :  10.1186/s12891-015-0523-4

 received in 2014-09-25, accepted in 2015-03-06,  发布年份 2015

【 摘 要 】

Background

Since the reference value is the core factor of the T-score calculation, it has a significant impact on the prevalence of osteoporosis. The purpose of this study was to determine the effects of using the Korean reference value on the prevalence of osteoporosis and on the prediction of fracture risk.

Methods

We used femoral neck bone mineral density (BMD) data from the Korea National Health and Nutrition Examination Survey (KNHANES) 2008–2011. The Korean reference was identified by the mean and standard deviation of men and women aged 20–29 years. We compared the prevalence and the fracture risk assessment tool (FRAX™) probability obtained from the Korean reference and the NHANES III reference.

Results

In men, the prevalence of osteoporosis increased when using the Korean men’s reference, and the difference increased up to 9% for those in their 80s. In women, the prevalence increased when using the NHANES III reference, and the difference increased up to 17% for those in their 80s. The reference value also affected the fracture risk probability, and the difference from changing the reference value increased in women and in subjects with more clinical fracture risk factors. In major osteoporotic fractures, the difference of the risk probability was up to 6% in women aged 70–79 years with two clinical risk factors. For femoral neck fractures, the difference was up to 7% in women aged 50–59 years with two clinical risk factors.

Conclusions

We confirmed that the reference value had significant effects on the prevalence of osteoporosis and on the fracture risk probability. The KNHANES 2008–2011 BMD data reflected the characteristics of the Korean BMD status well with regard to data size and study design; therefore, these data can be used as reference values.

【 授权许可】

   
2015 Lee et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Kanis JA: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 1994, 4:368-81.
• [2]Kanis JA, Glüer CC: An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 2000, 11:192-202.
• [3]Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N: A reference standard for the description of osteoporosis. Bone 2008, 42:467-75.
• [4]Tenenhouse A, Joseph L, Kreiger N, Poliquin S, Murray TM, Blondeau L, et al.: Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporosis Int 2000, 11:897-904.
• [5]Ribom EL, Ljunggren O, Mallmin H: Use of a Swedish T-score reference population for women causes a two-fold increase in the amount of postmenopausal Swedish patients that fulfill the WHO criteria for osteoporosis. J Clin Densitom 2008, 11:404-11.
• [6]Zhang Z, Ho SC, Chen ZQ, Zhang CX, Chen YM: Reference values of bone mineral density and prevalence of osteoporosis in Chinese adults. Osteoporosis Int 2014, 25:497-507.
• [7]Wong JC, Travers C, O’Neill S, Khoo SK: Towards validation of use of an Australian reference database for the diagnosis of osteoporosis with DXA. J Med Imaging Radiat Oncol 2012, 56:302-4.
• [8]Ho-Pham Lan T, Nguyen UD, Pham HN, Nguyen ND, Nguyen TV: Reference ranges for bone mineral density and prevalence of osteoporosis in Vietnamese men and women. BMC Musculoskelet Disord 2011, 10:182. BioMed Central Full Text
• [9]Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, et al.: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013, 24:23-57.
• [10]National Osteoporosis Foundation: Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington; 2010.
• [11]Baim S, Binkely N, Bilezikian JP, Kendler DL, Hans DB, Lewiecki EM, et al.: Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD position development conference. J Clin Densitom 2008, 1:75-91.
• [12]Kanis KJ, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. Technical report. World Health Organization Collaborating Centre for Metabolic Bone Disease: University of Sheffield; 2007.
• [13]Cummings SR, Melton LJ: Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-7.
• [14]Korthoewer D, Chandran M: Osteoporosis management and the utilization of FRAX®: a survey amongst health care professionals of the Asia-Pacific. Arch Osteoporos 2012, 7:193-200.
• [15]Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ: Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? New Engl J Med 2012, 366:2051-3.
• [16]Watts NB, Diab DL: Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010, 95:1555-65.
• [17]McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al.: Bisphosphonate therapy for osteoporosis: benefits, risks, and drug Holiday. Am J Med 2013, 126:13-20.
• [18]Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al.: Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 2006, 296:2927-38.
• [19]Compston JE, Bilezikian JP: Bisphosphonate therapy for osteoporosis: the long and short of it. J Bone Miner Res 2012, 27:240-2.
• [20]Korea Centers for Disease Control and Prevention. The Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV). [https://knhanes.cdc.go.kr/knhanes/]
• [21]Korea Centers for Disease Control and Prevention. The Fifth Korea National Health and Nutrition Examination Survey (KNHANES V). [https://knhanes.cdc.go.kr/knhanes/]
• [22]Centers for Disease Control and Prevention (CDC). National Health and Nutrition Examination Survey. [http://www.cdc.gov/nchs/nhanes.htm]
• [23]Looker AC, Wahner HW, Dunn WL, Calvo TB, Harris SP, Heyse SP, et al.: Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998, 8:468-89.
• [24]WHO fracture risk assessment tool FRAX® Korea version 3.8. South Yorkshire: University of Sheffield; 2014.
• [25]Mendoza N, Sánchez-Borrego R, Villero J, Baro F, Calaf J, Cancelo MJ, et al.: Up-date of the consensus statement of the Spanish Menopause Society on postmenopausal osteoporosis. Maturitas 2013, 76:99-107.
• [26]The Korean Society for Bone and Mineral Research: Physician’s guide for diagnosis & treatment of osteoporosis. The Korean Society for Bone and Mineral Research, Seoul; 2013.
• [27]Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, et al.: Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013, 75:392-6.
• [28]Lee J, Lee S, Jang S, Ryu OH: Age-related changes in the prevalence of osteoporosis according to gender and skeletal site: the Korea National Health and Nutrition Examination Survey 2008–2010. Endocrinol Metab (Seoul) 2013, 28:180-91.
• [29]Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B: Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989-95.
• [30]Kanis JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002, 359:1929-36.